Moors & Cabot’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-12,400	Closed	-$18.6K	–	886
2023 Q1	$18.6K	Hold	12,400	–	–	﹤0.01%	832
2022 Q4	$14.5K	Hold	12,400	–	–	﹤0.01%	827
2022 Q3	$14K	Hold	12,400	–	–	﹤0.01%	806
2022 Q2	$20K	Hold	12,400	–	–	﹤0.01%	786
2022 Q1	$19K	Hold	12,400	–	–	﹤0.01%	851
2021 Q4	$30K	Sell	12,400 -6,000	-33%	-$14K	﹤0.01%	849
2021 Q3	$47K	Sell	18,400 -4,960	-21%	-$12.7K	﹤0.01%	820
2021 Q2	$67K	Buy	23,360 +3,690	+19%	+$9.55K	﹤0.01%	784
2021 Q1	$46K	Buy	19,670 +3,920	+25%	+$9.41K	﹤0.01%	745
2020 Q4	$27K	Buy	15,750 +1,000	+7%	+$1.4K	﹤0.01%	718
2020 Q3	$14K	Sell	14,750 -1,400	-9%	-$1.24K	﹤0.01%	683
2020 Q2	$14K	Sell	16,150 -4,000	-20%	-$3.52K	﹤0.01%	650
2020 Q1	$15K	Hold	20,150	–	–	﹤0.01%	577
2019 Q4	$18K	Sell	20,150 -15,000	-43%	-$12.5K	﹤0.01%	601
2019 Q3	$34K	Sell	35,150 -3,000	-8%	-$3.11K	﹤0.01%	613
2019 Q2	$41K	Buy	38,150 +9,000	+31%	+$10.4K	0.01%	540
2019 Q1	$38K	Buy	29,150 +3,000	+11%	+$3.73K	0.01%	515
2018 Q4	$25K	Sell	26,150 -28,428	-52%	-$43.5K	﹤0.01%	497
2018 Q3	$111K	Buy	54,578 +1,943	+4%	+$4.08K	0.01%	560
2018 Q2	$94K	Sell	52,635 -7,292	-12%	-$14.7K	0.01%	540
2018 Q1	$141K	Buy	59,927 +7,178	+14%	+$16.8K	0.02%	549
2017 Q4	$99K	Sell	52,749 -1,006	-2%	-$2.2K	0.01%	545
2017 Q3	$135K	Sell	53,755 -2,972	-5%	-$7.37K	0.02%	514
2017 Q2	$154K	Buy	56,727 +11,430	+25%	+$31.9K	0.03%	483
2017 Q1	$134K	Buy	45,297 +6,058	+15%	+$17.2K	0.02%	483
2016 Q4	$124K	Buy	39,239 +26,666	+212%	+$81.9K	0.02%	508
2016 Q3	$44K	Buy	+12,573	New	+$34.7K	0.01%	530

Other funds holding LCTX